| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
L-Aspartic acid potassium does not have a specific pharmacological target. L-Aspartic acid is an amino acid that acts as a major neurotransmitter for fast synaptic excitation. It is involved in the malate-aspartate shuttle, which is critical for cellular energy metabolism. The potassium salt form provides potassium, an essential electrolyte. The compound is used as a nutrient supplement and a precursor for colon-specific drug delivery. In biochemical assays, it is used in the serum glutamate-oxaloacetate transaminase (SGOT) assay.
|
|---|---|
| ln Vitro |
In vitro, L-Aspartic acid potassium is used as a component of cell culture media and in biochemical assays. It is used to prepare perforated patch-clamp intracellular solutions for electrophysiology studies. It is also used in the serum glutamate-oxaloacetate transaminase (SGOT) assay. As an amino acid, it supports cell growth and metabolism in culture. It may serve as a precursor for colon-specific drug delivery systems. The compound is not a pharmacologically active drug but a biochemical reagent and nutrient.
|
| ln Vivo |
In vivo, L-Aspartic acid potassium is used as a dietary supplement to provide potassium and the amino acid aspartate. It may be used in the management of potassium deficiency. As a component of the malate-aspartate shuttle, aspartate plays a role in energy metabolism. However, the compound is not used as a therapeutic agent for specific diseases. It is generally recognized as safe for use as a nutrient supplement. It can be used as a suitable prodrug for colon-specific drug delivery.
|
| Enzyme Assay |
In vitro enzyme assays using L-Aspartic acid potassium include the serum glutamate-oxaloacetate transaminase (SGOT) assay, where it serves as a substrate. In this assay, aspartate and α-ketoglutarate are converted to oxaloacetate and glutamate by SGOT, and the oxaloacetate is measured. The compound is also used in electrophysiology to prepare intracellular solutions for patch-clamp recordings. No specific receptor binding assays are applicable as it is not a drug targeting a receptor.
|
| Cell Assay |
Cell-based assays for L-Aspartic acid potassium are limited to its use as a nutrient supplement in cell culture media. It supports cell growth and metabolism. The compound may be used in studies of amino acid transport and metabolism in cell lines. As a precursor for colon-specific drug delivery, it can be used in cell-based models of intestinal absorption and drug targeting. However, specific pharmacological assays are not applicable.
|
| Animal Protocol |
In vivo animal experiments with L-Aspartic acid potassium are limited to nutritional and metabolic studies. The compound may be administered orally or intravenously to assess its effects on potassium and amino acid levels. Studies on colon-specific drug delivery using L-aspartic acid as a prodrug may involve animal models. However, specific protocols are not extensively documented. The compound is generally used as a research reagent and nutrient supplement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of L-Aspartic acid potassium are not extensively characterized for pharmacological purposes. As an amino acid salt, it is absorbed from the gastrointestinal tract and distributed to tissues. Potassium is excreted primarily in the urine. The compound has a molecular formula of C4H6KNO4 and a molecular weight of 171.19. It is highly soluble in water. Storage: powder at room temperature, protected from moisture.
|
| Toxicity/Toxicokinetics |
L-Aspartic acid potassium is generally recognized as safe (GRAS) when used as a nutrient supplement. At high doses, it may cause gastrointestinal discomfort. As a potassium salt, excessive intake may lead to hyperkalemia in individuals with renal impairment. The compound is for research use and as a dietary supplement; not for therapeutic use without appropriate medical supervision. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
A common non-essential amino acid, existing in its L-form. It is found in both plants and animals, particularly in sugarcane and sugar beets. It may be a neurotransmitter.
L-Aspartic acid potassium has CAS number 1115-63-5, molecular formula C4H6KNO4, and molecular weight 171.19. It is the monopotassium salt of L-aspartic acid. It is a highly soluble, chloride-free organic potassium source. L-Aspartic acid is a non-essential amino acid and may be a neurotransmitter. It can be used as a precursor for colon-specific drug delivery. Purity is typically ≥99%. Not for human use as a drug without appropriate formulation; for research and supplement applications. |
| Molecular Formula |
C4H5K2NO4
|
|---|---|
| Molecular Weight |
209.2834
|
| Exact Mass |
169.986
|
| CAS # |
1115-63-5
|
| Related CAS # |
L-Aspartic acid;56-84-8;Aspartic acid calcium;10389-09-0;L-Aspartic aicd sodium;3792-50-5
|
| PubChem CID |
23672742
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
270-271ºC
|
| Index of Refraction |
20.5 ° (C=8, 6mol/L HCl)
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
10
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[K+].[K+].[O-]C([C@]([H])(C([H])([H])C(=O)[O-])N([H])[H])=O
|
| InChi Key |
TXXVQZSTAVIHFD-DKWTVANSSA-M
|
| InChi Code |
InChI=1S/C4H7NO4.K/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+1/p-1/t2-;/m0./s1
|
| Chemical Name |
potassium;(2S)-2-amino-4-hydroxy-4-oxobutanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7783 mL | 23.8914 mL | 47.7829 mL | |
| 5 mM | 0.9557 mL | 4.7783 mL | 9.5566 mL | |
| 10 mM | 0.4778 mL | 2.3891 mL | 4.7783 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
